Business Description
![BioLine Rx Ltd BioLine Rx Ltd logo](https://static.gurufocus.com/logos/0C0000353L.png?14)
BioLine Rx Ltd
ISIN : IL0011015182
Compare
Compare
Traded in other countries / regions
BLRX.IsraelBLRX.USAYP2A.Germany IPO Date
2007-02-11Description
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.49 | |||||
Equity-to-Asset | 0.25 | |||||
Debt-to-Equity | 0.87 | |||||
Debt-to-EBITDA | -0.25 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -12.32 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 18.4 | |||||
3-Year EPS without NRI Growth Rate | 25 | |||||
3-Year FCF Growth Rate | 36.3 | |||||
3-Year Book Growth Rate | -42 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 60.14 | |||||
9-Day RSI | 63.21 | |||||
14-Day RSI | 61.95 | |||||
6-1 Month Momentum % | -48.75 | |||||
12-1 Month Momentum % | -56.15 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.14 | |||||
Quick Ratio | 1.05 | |||||
Cash Ratio | 0.9 | |||||
Days Inventory | 517.98 | |||||
Days Sales Outstanding | 49.95 | |||||
Days Payable | 2078.89 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -46 | |||||
Shareholder Yield % | -4.45 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 87.52 | |||||
Operating Margin % | -334.26 | |||||
Net Margin % | -421.69 | |||||
FCF Margin % | -247.97 | |||||
ROE % | -246.76 | |||||
ROA % | -83.03 | |||||
ROIC % | -127.34 | |||||
ROC (Joel Greenblatt) % | -2299.83 | |||||
ROCE % | -120.82 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 4.9 | |||||
PB Ratio | 4.34 | |||||
EV-to-EBIT | -0.98 | |||||
EV-to-Forward-EBIT | -1.14 | |||||
EV-to-EBITDA | -1.02 | |||||
EV-to-Forward-EBITDA | -1.14 | |||||
EV-to-Revenue | 3.94 | |||||
EV-to-Forward-Revenue | 2.68 | |||||
EV-to-FCF | -1.58 | |||||
Earnings Yield (Greenblatt) % | -102.04 | |||||
FCF Yield % | -46.16 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BioLine Rx Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil ₪) | 42.648 | ||
EPS (TTM) (₪) | -0.185 | ||
Beta | 0 | ||
Volatility % | 62.39 | ||
14-Day RSI | 61.95 | ||
14-Day ATR (₪) | 0.009832 | ||
20-Day SMA (₪) | 0.1698 | ||
12-1 Month Momentum % | -56.15 | ||
52-Week Range (₪) | 0.147 - 0.7 | ||
Shares Outstanding (Mil) | 1,199.09 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
BioLine Rx Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
BioLine Rx Ltd Stock Events
Event | Date | Price(₪) | ||
---|---|---|---|---|
No Event Data |
BioLine Rx Ltd Frequently Asked Questions
What is BioLine Rx Ltd(XTAE:BLRX)'s stock price today?
The current price of XTAE:BLRX is ₪0.19. The 52 week high of XTAE:BLRX is ₪0.70 and 52 week low is ₪0.15.
When is next earnings date of BioLine Rx Ltd(XTAE:BLRX)?
The next earnings date of BioLine Rx Ltd(XTAE:BLRX) is 2024-08-30 Est..
Does BioLine Rx Ltd(XTAE:BLRX) pay dividends? If so, how much?
BioLine Rx Ltd(XTAE:BLRX) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |